Pharma: Other news to note
Wednesday, December 11, 2013
Baxter International Inc., of Deerfield, Ill., said it submitted a biologics license application for the approval of OBI-1, a recombinant antihemophilic porcine sequence Factor VIII, in patients with acquired hemophilia A.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.